Genentech growth marketing leader Tiffany William has built a reputation for applying lessons from the mobile gaming world to pharmaceutical marketing strategy. William, based in the San Francisco Bay Area, leads growth
More
The U.S. Food and Drug Administration has issued an untitled letter to Alar Pharmaceuticals over misleading promotional claims about an investigational ketamine treatment. The FDA’s Office of Prescription Drug Promotion issued the
More
New research from Bausch + Lomb has found that dry eye disease remains one of the least recognised conditions affecting women during and after menopause. The survey highlights a significant gap in
More
AstraZeneca (AZN) appears to be stepping back from combination therapy approaches in transthyretin amyloid cardiomyopathy following a significant phase 3 clinical failure. The setback involved Wainua, a drug developed in partnership with
More
Meeting the legal requirements of DSCSA and building genuine operational efficiency are two very different things, according to a senior industry figure. Gregg Gorniak, vice president of manufacturer operations and data services
More
Novartis has announced positive topline results from its Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib is a highly selective and potent oral Bruton’s tyrosine kinase inhibitor
More
The pharmaceutical industry faces mounting pressure as blockbuster drug patents expire, opening markets to both generic and biosimilar competitors across the globe. Patent cliffs represent moments when brand-name drug manufacturers lose exclusivity,
More
Emergent BioSolutions (NYSE: EBS) is ramping up its opioid overdose education efforts across North America in recognition of International Overdose Awareness Day. The company is targeting college campuses across the United States
More
The FDA is pressing ahead with national licensure standards for wholesale distributors and third-party logistics providers, raising urgent questions across the pharmaceutical supply chain. At the heart of the debate is whether
More
The White House has announced a second wave of most favoured nation drug pricing agreements, this time targeting nine medium-sized pharmaceutical companies across multiple continents. The latest round includes Alcon, Astellas Pharma,
More